BR112014007491B1 - Composição de vacina e usos de um peptídeo - Google Patents
Composição de vacina e usos de um peptídeo Download PDFInfo
- Publication number
- BR112014007491B1 BR112014007491B1 BR112014007491-7A BR112014007491A BR112014007491B1 BR 112014007491 B1 BR112014007491 B1 BR 112014007491B1 BR 112014007491 A BR112014007491 A BR 112014007491A BR 112014007491 B1 BR112014007491 B1 BR 112014007491B1
- Authority
- BR
- Brazil
- Prior art keywords
- oreochromicin
- peptides
- peptide
- group
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 158
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 229960005486 vaccine Drugs 0.000 title claims abstract description 14
- 244000052769 pathogen Species 0.000 claims abstract description 20
- 239000002671 adjuvant Substances 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 72
- 102000044503 Antimicrobial Peptides Human genes 0.000 abstract description 42
- 108700042778 Antimicrobial Peptides Proteins 0.000 abstract description 42
- 241000276707 Tilapia Species 0.000 abstract description 19
- 241000894006 Bacteria Species 0.000 abstract description 18
- 230000000845 anti-microbial effect Effects 0.000 abstract description 15
- 230000014509 gene expression Effects 0.000 abstract description 12
- 241000276703 Oreochromis niloticus Species 0.000 abstract description 11
- 241000700605 Viruses Species 0.000 abstract description 10
- 241000233866 Fungi Species 0.000 abstract description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 7
- 150000001413 amino acids Chemical group 0.000 abstract description 7
- 230000001717 pathogenic effect Effects 0.000 abstract description 7
- 239000000284 extract Substances 0.000 abstract description 4
- 210000002816 gill Anatomy 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 241000192125 Firmicutes Species 0.000 abstract 1
- 238000001823 molecular biology technique Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 49
- 108010058846 Ovalbumin Proteins 0.000 description 42
- 229940092253 ovalbumin Drugs 0.000 description 42
- 235000019688 fish Nutrition 0.000 description 40
- 241000251468 Actinopterygii Species 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 238000002649 immunization Methods 0.000 description 15
- 230000003053 immunization Effects 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 241000235058 Komagataella pastoris Species 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000007928 intraperitoneal injection Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 125000003345 AMP group Chemical group 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 231100000636 lethal dose Toxicity 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
- 230000004523 agglutinating effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000028996 humoral immune response Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 241000607534 Aeromonas Species 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000607528 Aeromonas hydrophila Species 0.000 description 2
- 101710150620 Anionic peptide Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- 241000701372 Iridovirus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DSLBDPPHINVUID-REOHCLBHSA-N (2s)-2-aminobutanediamide Chemical compound NC(=O)[C@@H](N)CC(N)=O DSLBDPPHINVUID-REOHCLBHSA-N 0.000 description 1
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 101150061183 AOX1 gene Proteins 0.000 description 1
- 241001578974 Achlya <moth> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101150009006 HIS3 gene Proteins 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 description 1
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 1
- 241000546112 Infectious salmon anemia virus Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000863434 Myxococcales Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000269979 Paralichthys olivaceus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 241000467915 Rana grylio iridovirus Species 0.000 description 1
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 241000233667 Saprolegnia Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241001479108 Snakehead virus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010072542 endotoxin binding proteins Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004943 gill filament Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fodder In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2011-0181 | 2011-09-30 | ||
| CU20110181A CU24076B1 (es) | 2011-09-30 | 2011-09-30 | Composición para el control de patógenos |
| PCT/CU2012/000005 WO2013044890A1 (es) | 2011-09-30 | 2012-10-01 | Secuencias de aminoácidos para el control de patógenos |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014007491A2 BR112014007491A2 (pt) | 2017-04-04 |
| BR112014007491B1 true BR112014007491B1 (pt) | 2022-03-03 |
Family
ID=47143463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014007491-7A BR112014007491B1 (pt) | 2011-09-30 | 2012-10-01 | Composição de vacina e usos de um peptídeo |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9549978B2 (enExample) |
| EP (1) | EP2767290B1 (enExample) |
| JP (1) | JP6034385B2 (enExample) |
| KR (1) | KR101986358B1 (enExample) |
| CN (1) | CN103874502B (enExample) |
| AR (1) | AR088176A1 (enExample) |
| AU (1) | AU2012315083B2 (enExample) |
| BR (1) | BR112014007491B1 (enExample) |
| CA (1) | CA2849040C (enExample) |
| CL (1) | CL2014000760A1 (enExample) |
| CU (1) | CU24076B1 (enExample) |
| ES (1) | ES2600903T3 (enExample) |
| MX (1) | MX348934B (enExample) |
| RU (1) | RU2636001C2 (enExample) |
| WO (1) | WO2013044890A1 (enExample) |
| ZA (1) | ZA201402171B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104262485B (zh) * | 2014-04-15 | 2017-01-18 | 四川农业大学 | 罗非鱼sIgM截短重链恒定区蛋白多克隆抗体及其制备方法 |
| CN105061575B (zh) * | 2015-02-03 | 2020-08-04 | 浙江海洋学院 | 一种金枪鱼肝脏抗菌肽及其制备方法和用途 |
| CN109350731A (zh) * | 2018-12-18 | 2019-02-19 | 汕尾市维明生物科技股份有限公司 | 一种罗非鱼蛋白肽在制备免疫制剂中的应用 |
| CN112979763A (zh) * | 2021-03-03 | 2021-06-18 | 山东大学 | 一种基于可溶性疏水载体抗菌肽Oreoch-2的液相合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030056244A1 (en) * | 2000-05-02 | 2003-03-20 | Ning Huang | Feed additive compositions and methods |
| US6753407B2 (en) * | 2000-08-15 | 2004-06-22 | North Carolina State University | Antimicrobial peptides isolated from fish |
| AU2001287178A1 (en) * | 2000-08-15 | 2002-02-25 | North Carolina State University | Antimicrobial peptides isolated from mast cells |
| WO2004018706A2 (en) * | 2002-08-22 | 2004-03-04 | National Research Council Of Canada | A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish |
| EP1838331A4 (en) * | 2004-12-15 | 2012-12-26 | Univ Colorado | ANTIMICROBIAL PEPTIDES AND METHOD OF USE |
| RU2302467C1 (ru) * | 2005-12-01 | 2007-07-10 | Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук | Пептиды латарцины, проявляющие антимикробную активность |
| US20090186047A1 (en) * | 2006-04-25 | 2009-07-23 | Intercell Ag | HCV Vaccinations |
| TWI299335B (en) * | 2006-12-05 | 2008-08-01 | Academia Sinica | Anti-microbal peptides and uses thereof |
| WO2009149554A1 (en) * | 2008-06-11 | 2009-12-17 | National Research Council Of Canada | Antimicrobial components of the mucus and extruded slime of hagfish (myxine glutinosa) |
| CN103665170A (zh) * | 2008-12-05 | 2014-03-26 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| US20100184684A1 (en) * | 2009-01-06 | 2010-07-22 | C3 Jian, Inc. | Antibacterial and antifungal peptides |
| US8389679B2 (en) * | 2009-02-05 | 2013-03-05 | The Regents Of The University Of California | Targeted antimicrobial moieties |
| CN101559214A (zh) * | 2009-05-27 | 2009-10-21 | 珍奥集团股份有限公司 | 具有增强免疫功能作用的组合物及其用途 |
| CN102021172A (zh) * | 2010-06-23 | 2011-04-20 | 广西壮族自治区水产研究所 | 罗非鱼白细胞 cAMP 诱导早期抑制因子基因序列及用途 |
| EP2661451B1 (en) * | 2011-01-07 | 2019-10-09 | Valiant Biopharma SDN BHD | Antimicrobial fusion compounds and uses thereof |
-
2011
- 2011-09-30 CU CU20110181A patent/CU24076B1/es active IP Right Grant
-
2012
- 2012-09-27 AR ARP120103606A patent/AR088176A1/es unknown
- 2012-10-01 CN CN201280050943.4A patent/CN103874502B/zh active Active
- 2012-10-01 EP EP12783080.0A patent/EP2767290B1/en not_active Not-in-force
- 2012-10-01 JP JP2014532244A patent/JP6034385B2/ja active Active
- 2012-10-01 CA CA2849040A patent/CA2849040C/en active Active
- 2012-10-01 WO PCT/CU2012/000005 patent/WO2013044890A1/es not_active Ceased
- 2012-10-01 RU RU2014117659A patent/RU2636001C2/ru active
- 2012-10-01 AU AU2012315083A patent/AU2012315083B2/en active Active
- 2012-10-01 MX MX2014003892A patent/MX348934B/es active IP Right Grant
- 2012-10-01 KR KR1020147009805A patent/KR101986358B1/ko active Active
- 2012-10-01 BR BR112014007491-7A patent/BR112014007491B1/pt active IP Right Grant
- 2012-10-01 ES ES12783080.0T patent/ES2600903T3/es active Active
- 2012-10-01 US US14/346,562 patent/US9549978B2/en active Active
-
2014
- 2014-03-24 ZA ZA2014/02171A patent/ZA201402171B/en unknown
- 2014-03-27 CL CL2014000760A patent/CL2014000760A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201402171B (en) | 2015-12-23 |
| CU24076B1 (es) | 2015-01-29 |
| KR101986358B1 (ko) | 2019-06-05 |
| CA2849040C (en) | 2019-11-26 |
| ES2600903T3 (es) | 2017-02-13 |
| KR20140070597A (ko) | 2014-06-10 |
| AR088176A1 (es) | 2014-05-14 |
| RU2014117659A (ru) | 2015-11-10 |
| CA2849040A1 (en) | 2013-04-04 |
| CL2014000760A1 (es) | 2014-08-22 |
| CU20110181A7 (es) | 2013-05-31 |
| US9549978B2 (en) | 2017-01-24 |
| US20140294871A1 (en) | 2014-10-02 |
| MX348934B (es) | 2017-07-03 |
| EP2767290A1 (en) | 2014-08-20 |
| WO2013044890A1 (es) | 2013-04-04 |
| AU2012315083A1 (en) | 2014-05-08 |
| AU2012315083B2 (en) | 2016-02-25 |
| BR112014007491A2 (pt) | 2017-04-04 |
| CN103874502B (zh) | 2015-11-25 |
| CN103874502A (zh) | 2014-06-18 |
| EP2767290B1 (en) | 2016-09-14 |
| JP6034385B2 (ja) | 2016-11-30 |
| RU2636001C2 (ru) | 2017-11-17 |
| MX2014003892A (es) | 2014-07-09 |
| JP2014533931A (ja) | 2014-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leung et al. | The yopM gene of Yersinia pestis encodes a released protein having homology with the human platelet surface protein GPIb alpha | |
| RU2646137C2 (ru) | КОМПОЗИЦИЯ ПО ПРЕДУПРЕЖДЕНИЮ ИНФЕКЦИИ Mycoplasma spp. | |
| BR112014007491B1 (pt) | Composição de vacina e usos de um peptídeo | |
| Sathyamoorthi et al. | Therapeutic cationic antimicrobial peptide (CAP) derived from fish aspartic proteinase Cathepsin D and its antimicrobial mechanism | |
| Lazarev et al. | Antimicrobial peptides and their use in medicine | |
| Ma et al. | Three novel Anas platyrhynchos avian β-defensins, upregulated by duck hepatitis virus, with antibacterial and antiviral activities | |
| JP3072345B1 (ja) | 豚丹毒菌の組換えサブユニットワクチン | |
| Wang et al. | Molecular characterization, phylogenetic analysis and adjuvant effect of channel catfish interleukin-1βs against Streptococcus iniae | |
| CN112480227B (zh) | 一种提高鲟鱼抵抗病原菌能力的蛋白及其制备方法与应用 | |
| KR100854594B1 (ko) | 톨-유사 수용체-5 자극 활성이 강화된 ｐａｓ-플라젤린융합 단백질 | |
| Wang et al. | Molecular characteristics of interleukin (IL)-17A/F3 and its immune response on the pathogen and functional regulation on cytokines in common carp Cyprinus carpio L. | |
| Nuñez-Ortiz et al. | Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout | |
| SE462285B (sv) | Expression av koleratoxinets bindande subenhet med hjaelp av fraemmande promotor- och/eller ledarpeptidstrukturer | |
| CA2873599A1 (en) | Peptides inducing an immune response against copepods and/or the development of a mucous shield in fish; vaccines, uses and methods for modulating the fish immune response and/or for inducing development of a mucous shield in fish | |
| KR100823866B1 (ko) | 톨-유사 수용체-5 자극 활성이 증가된 플라젤린 변형체 | |
| CN116284281B (zh) | G型产气荚膜梭菌的重组蛋白、疫苗及应用 | |
| US20240092834A1 (en) | Inhibition of degranulation of neutrophil cells in covid-19 patients | |
| Wilson et al. | Milk-derived antimicrobial peptides to protect against Neonatal Diarrheal Disease: An alternative to antibiotics | |
| CN109628460A (zh) | 一种超深渊来源抗菌肽hydramacin及其制备方法 | |
| Shen et al. | Structure, biological properties and utilities of marine-derived antimicrobial peptides | |
| BR102023023411A2 (pt) | Molécula de ácido nucleico recombinante, epítopo de alfa toxina de c. novyi recombinante e seu uso, vetor de expressão, composição vacinal, método para prevenir ou tratar clostridioses em um indivíduo sofrendo do mesmo e método para produzir uma composição vacinal contra clostridiose | |
| US12329789B2 (en) | Transformed, Salmo salar interferon gamma (IFNg)-producing Lactococcus lactis bacterium, food and composition comprising same, for immunostimulation in aquaculture species | |
| KR101919314B1 (ko) | 구제역 바이러스 백신 조성물 | |
| JP2018016548A (ja) | 抗微生物ポリペプチド | |
| ALOBAIDI | molecular cloning, phylogenetic analysis, and expression of two immune related genes, serum amyloid a and c-reactive protein from asian seabass Lates calcarifer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/10/2012, OBSERVADAS AS CONDICOES LEGAIS. |